Navigation Links
Quest Diagnostics Introduces Molecular Blood Test for Aiding Colorectal Cancer Detection
Date:1/11/2010

MADISON, N.J., Jan. 11 /PRNewswire-FirstCall/ -- A new blood test that identifies changes in DNA associated with colorectal cancer is now available in the U.S. through Quest Diagnostics Incorporated (NYSE: DGX), the world's leading cancer diagnostics company. The test is designed to aid the detection of colorectal cancer, the third leading cause of cancer-related deaths.

The new test is based on DNA methylation of the Septin9 gene, a proprietary biomarker associated with colorectal cancer that was identified by Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer molecular diagnostics company. Quest Diagnostics is the first commercial laboratory in the U.S. to offer a laboratory-developed test based on the Septin9 biomarker.

"Early detection rates are dismally low, largely because many patients find existing tests and procedures invasive or unpleasant," said Jon R. Cohen, M.D. senior vice president and chief medical officer, Quest Diagnostics. "Our ColoVantage(TM) test, which is based on Septin9, has yet to be clinically validated as a screening test. Rather, it may promote further evaluation in patients who have resisted testing in the past or as an adjunct to existing procedures."

Colorectal cancer treated in localized, early stages has a five-year survival rate of 90 percent. Yet, only 40 percent of cases are diagnosed in early stages, due to low screening rates.

Epigenomics has demonstrated in more than a half dozen peer-reviewed studies involving approximately 3,000 specimens of patients with diagnosed colorectal cancer and of healthy control subjects that methylated Septin9 in blood plasma indicates an increased likelihood of colorectal cancer. Epigenomics is sponsoring a multi-center clinical study named PRESEPT in collaboration with Quest Diagnostics and other organizat
'/>"/>

SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Quest Diagnostics Declares Quarterly Cash Dividend
2. HemaQuest Pharmaceuticals Presents Promising Results in Sickle Cell Disease and Beta Thalassemia
3. MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug"
4. Hungarian Cancer Formula Producer Questions U.S. Introduction of AveUltra
5. SciScout LLC Launches SciAnswers.com, a Science-Based Questions and Answers (Q&A) Site with a Social Networking Perspective.
6. GenomeQuest Places ChIP-Seq Workflow Solution On SDM “Cloud”
7. Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline
8. GeoVax Labs Requests pre-IND Meeting With FDA
9. Stemedica Requests Pre-IND Meeting With FDA
10. Five Questions About Protopic (tacrolimus) Ointment
11. FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics Focus Diagnostics Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... ZIONA, Israel , September 29, 2014 ... company developing novel immunomodulators for severe infections, today announced ... BARDA ) has awarded Atox Bio with a contract ... the development of AB103 to treat Necrotizing Soft Tissue ... public health threats that end in sepsis. ...
(Date:9/29/2014)... September 29, 2014 Florais de Saint ... its natural and soul-enhancing floral essences to the United ... essences into special formulas to help with specific treatments ... physical, mental, and emotional health. , “This is truly ... discoveries being made every day on how to properly ...
(Date:9/27/2014)... special section on single-photon detection, generation, and applications ... technologies with applications in areas as diverse as ... by providing more accurate measurement methods and new ... SPIE, the international society for optics and photonics, ... , The section appears in the August issue, ...
(Date:9/26/2014)... 2014 Synedgen announced today the ... (SBIR) Phase I contract from the National Cancer ... (NIH) to demonstrate proof-of-concept activity of Synedgen’s proprietary ... painful tissue damage to the lining of the ... this award, Synedgen will complete efficacy studies for ...
Breaking Biology Technology:Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA) 2Florais de Saint Germain Brings New Kind of Flower Power To America 2Single-photon detection, generation, and applications featured in Optical Engineering 2Single-photon detection, generation, and applications featured in Optical Engineering 3Synedgen Awarded National Cancer Institute Funding for Promising New Treatment for Medical Radiation-induced Bowel Injury 2
... , , SAN FRANCISCO, Aug. 4 Nile ... the development of novel therapeutics for heart failure patients, today announced ... of its lead product, CD-NP, for the treatment of acute heart ... study is designed to provide additional information on the safety and ...
... /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) ... Hausman, M.D., as Vice President, Clinical Development at Oncothyreon. ... planning and implementing the clinical development program for the ... is an experienced oncologist who brings an extensive background ...
... , PALO ALTO, Calif., August ... antiviral therapies, announced today that it has licensed the exclusive ... Stanford University. This technology, discovered in the lab of Stanford ... focused on a variety of novel targets, including key features ...
Cached Biology Technology:Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure 2Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure 3Oncothyreon appoints Diana Hausman as Vice President of Clinical Development 2Oncothyreon appoints Diana Hausman as Vice President of Clinical Development 3Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University 2
(Date:9/29/2014)... Energy Joint Genome Institute (DOE JGI), a DOE ... 32 new projects have been selected for the ... lakes to Caribbean waters, and from plant root ... in forested watersheds, the CSP 2015 projects portfolio ... be extracted. , "These projects catalyze JGI,s ...
(Date:9/29/2014)... who lived 2,330 years ago in the southernmost tip of ... when his DNA profile is one of the ,earliest diverged, ... region where modern humans are believed to have originated roughly ... ,mitochondrial DNA, was sequenced to provide clues to early modern ... that we all come from Africa, and helps us map ...
(Date:9/29/2014)... Ill. Scientists have discovered a previously unknown ... grow and, in the case of estrogen-positive breast ... work reveals new targets for breast cancer therapy ... the most aggressive treatment. , The University of ... Oncogene . , Estrogen pre-activates the unfolded-protein ...
Breaking Biology News(10 mins):2015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9Ancient human genome from southern Africa throws light on our origins 2Ancient human genome from southern Africa throws light on our origins 3Scientists discover a new role for estrogen in the pathology of breast cancer 2
... Hopkins researchers have created a synthetic protein that, when activated ... body where cancer, arthritis and other serious medical disorders can ... type of diagnostic imaging technology and may someday serve as ... where signs of disease have been found. In a study ...
... mood for food can be changed by a restaurant,s choice ... calorie intake, according to a new study., "When we did ... music and lighting led diners to eat 175 fewer calories ... Wansink, professor of marketing and director of Cornell University,s Food ...
... FARMINGTON, Conn., Aug. 29, 2012 /PRNewswire-iReach/ -- The biobanking market ... new drug and treatment development for specific diseases. The ... and is projected to increase by 30% between 2010 and ... Private sector biobanks will experience the greatest increase with growth ...
Cached Biology News:Collagen-seeking synthetic protein could lead doctors to tumor locations 2Collagen-seeking synthetic protein could lead doctors to tumor locations 3Global Biobanking Market Projected to Increase by 30% to Reach $183 Billion by 2015 2Global Biobanking Market Projected to Increase by 30% to Reach $183 Billion by 2015 3
...
One-step, microplate or cuvet, colorimetric, detection range 0.3 g/dL to 5 g/dL. Procedure: 5 min....
Donor Goat Serum...
The Varian 4000 GC/MS system offers three easily switchable ionization configurations: internal ionization (II), external ionization (EI) or hybrid chemical ionization (CI)...
Biology Products: